• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Adverse events and preventive measures related to COVID-19 vaccines.与新冠病毒疫苗相关的不良事件及预防措施
Clin Exp Emerg Med. 2021 Sep;8(3):153-159. doi: 10.15441/ceem.21.067. Epub 2021 Sep 30.
2
Anaphylaxis is a rare reaction in COVID-19 vaccination.在 COVID-19 疫苗接种中,过敏反应较为罕见。
J Biol Regul Homeost Agents. 2021 May-Jun;35(3):839-842. doi: 10.23812/BELLOMO_EDIT_3_21.
3
COVID-19 vaccines: concerns beyond protective efficacy and safety.COVID-19 疫苗:除了保护效力和安全性之外的关注点。
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.
4
Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations.当前可用的COVID-19疫苗的过敏反应:病理生理学、因果关系及治疗考量
Vaccines (Basel). 2021 Mar 5;9(3):221. doi: 10.3390/vaccines9030221.
5
Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021.COVID-19 疫苗追加剂量的安全性监测 - 美国,2021 年 8 月 12 日至 9 月 19 日。
MMWR Morb Mortal Wkly Rep. 2021 Oct 1;70(39):1379-1384. doi: 10.15585/mmwr.mm7039e4.
6
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.在报告 Janssen(强生)和 mRNA COVID-19 疫苗(辉瑞-生物科技和莫德纳)成年受种者发生不良事件后使用 COVID-19 疫苗:免疫实践咨询委员会的更新-美国,2021 年 7 月。
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4.
7
Allergic reactions to Japanese encephalitis vaccine.对日本脑炎疫苗的过敏反应。
Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. doi: 10.1016/s0889-8561(03)00102-4.
8
Management of patients at risk of anaphylaxis after COVID 19 vaccination.COVID-19 疫苗接种后发生过敏反应风险患者的管理。
J Biol Regul Homeost Agents. 2021 May-Jun;35(3):843-846. doi: 10.23812/21-20-E.
9
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗:辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
10
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.美国 2020 年 12 月 14 日至 23 日:在接种第一剂辉瑞-BioNTech COVID-19 疫苗后出现过敏反应(包括过敏反应)。
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.

引用本文的文献

1
Post-vaccination incidence and side effects of COVID-19 in a cohort of Brazilian healthcare professionals: an internet-based survey.接种疫苗后巴西医护人员中 COVID-19 的发病和副作用:一项基于互联网的调查。
Einstein (Sao Paulo). 2022 Nov 25;20:eAO0067. doi: 10.31744/einstein_journal/2022AO0067. eCollection 2022.

本文引用的文献

1
Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database.对向欧洲药品不良反应数据库报告的新冠阿斯利康疫苗血栓形成不良反应的分析。
Vaccines (Basel). 2021 Apr 16;9(4):393. doi: 10.3390/vaccines9040393.
2
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.单剂 Ad26.COV2.S 疫苗预防新冠病毒的安全性和有效性。
N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21.
3
Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots.新冠疫情:有报道称出现血栓后,欧洲多国暂停使用牛津-阿斯利康疫苗。
BMJ. 2021 Mar 11;372:n699. doi: 10.1136/bmj.n699.
4
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19(阿斯利康)疫苗免疫原性和有效性的影响:四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
5
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.2020年12月14日至2021年1月18日美国接种mRNA新冠疫苗后发生过敏反应的报告
JAMA. 2021 Mar 16;325(11):1101-1102. doi: 10.1001/jama.2021.1967.
6
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性:俄罗斯一项随机对照 3 期临床试验的中期分析。
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
7
Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns.报告的 COVID-19 疫苗的口腔颌面部不良反应:已知和未知。
J Oral Pathol Med. 2021 Apr;50(4):424-427. doi: 10.1111/jop.13165. Epub 2021 Feb 19.
8
Impact of COVID-19 on acute isolation bed capacity and nursing workforce requirements: A retrospective review.新冠疫情对急性隔离床位容量和护理人力需求的影响:一项回顾性研究。
J Nurs Manag. 2021 Jul;29(5):1220-1227. doi: 10.1111/jonm.13260. Epub 2021 Feb 8.
9
Maintaining Safety with SARS-CoV-2 Vaccines.通过新冠病毒疫苗维持安全性。
N Engl J Med. 2021 Feb 18;384(7):643-649. doi: 10.1056/NEJMra2035343. Epub 2020 Dec 30.
10
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.在一项 1/2 期临床试验中,单次接种 ChAdOx1 nCoV-19(AZD1222)疫苗诱导的 T 细胞和抗体反应。
Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5. Epub 2020 Dec 17.

与新冠病毒疫苗相关的不良事件及预防措施

Adverse events and preventive measures related to COVID-19 vaccines.

作者信息

Ahn Tae Kyu, Kang Soo, Paik Jin Hui, Seo Young Ho

机构信息

Department of Emergency Medicine, Inha University School of Medicine, Incheon, Korea.

出版信息

Clin Exp Emerg Med. 2021 Sep;8(3):153-159. doi: 10.15441/ceem.21.067. Epub 2021 Sep 30.

DOI:10.15441/ceem.21.067
PMID:34649403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8517461/
Abstract

The coronavirus disease 2019 (COVID-19) vaccines are categorized according to the manufacturing technique, including mRNA vaccines and adenovirus vector vaccines. According to previous studies, the reported efficacy of the COVID-19 vaccine is excellent regardless of the type of vaccine, and the majority of studies have shown similar results for safety. Most of the adverse reactions after vaccination were mild or moderate grade, and severe reactions were reported in a very small proportion. However, the adverse reactions that might occur after nationwide vaccinations can contribute to crowding of emergency departments, and this can further lead to significant obstacles to providing necessary treatment for life-threatening conditions. Therefore, as emergency physicians, we would like to present some concerns and suggestions to prevent these predictable problems.

摘要

2019冠状病毒病(COVID-19)疫苗根据生产技术进行分类,包括信使核糖核酸(mRNA)疫苗和腺病毒载体疫苗。根据以往研究,无论疫苗类型如何,所报道的COVID-19疫苗效力都很出色,并且大多数研究表明在安全性方面也有类似结果。接种疫苗后的不良反应大多为轻度或中度,严重反应的报告比例非常小。然而,全国范围接种疫苗后可能出现的不良反应会导致急诊科人满为患,进而可能给危及生命状况的必要治疗造成重大障碍。因此,作为急诊医生,我们想提出一些担忧和建议以预防这些可预见的问题。